Norada Entities

This docket consolidates securities-fraud claims against Norada-affiliated entities, centralized before Judge Michelle Williams Court in the Central District of California in August 2026. With 46 actions filed and pending as of the JPML's most recent report, this is a young docket, formed only weeks before the report date, and the underlying allegations, defendant structure, and claim theories are still in an early developmental phase in this specific federal proceeding.

For a funder, a docket this new carries the risk profile typical of freshly centralized securities litigation: there is no bellwether track record, no ruling on the sufficiency of the fraud allegations, and no established damages methodology specific to this proceeding to benchmark against. Underwriting at this stage depends heavily on the individual claimant's investment documentation, transaction timeline, and the specific representations alleged to have been made, rather than on docket-wide precedent that has not yet developed.

There is no medical-lien component to this securities-fraud matter. For a claimant or firm building an early inventory of claims tied to this litigation, Criterica Capital's commercial litigation finance line is the applicable structure, though terms should reflect the significant uncertainty inherent in a docket this early in its development, including the likelihood that additional claims are transferred in or newly filed as the litigation matures. A structural brief tracking this docket's early development is available through Criterica Intelligence.

Pre-settlement funding is a non-recourse purchase of a portion of the proceeds of a pending legal claim — not a loan. If the case does not result in a recovery, nothing is owed. Rates, fees, and repayment terms are disclosed in full in the funding agreement, which the applicant’s attorney reviews before signing. Availability and terms vary by state.